Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $10,514 | $14,181 | $20,061 | $21,967 |
| - Cash | $1,021 | $3,729 | $7,851 | $5,045 |
| + Debt | $875 | $382 | $533 | $612 |
| Enterprise Value | $10,369 | $10,834 | $12,743 | $17,534 |
| Revenue | $4,800 | $3,959 | $4,532 | $4,154 |
| % Growth | 21.2% | -12.7% | 9.1% | – |
| Gross Profit | $2,796 | -$1,981 | -$1,223 | -$1,546 |
| % Margin | 58.3% | -50% | -27% | -37.2% |
| EBITDA | -$5,305 | -$4,883 | -$5,941 | -$5,061 |
| % Margin | -110.5% | -123.3% | -131.1% | -121.8% |
| Net Income | -$5,598 | -$6,419 | -$6,291 | -$5,460 |
| % Margin | -116.6% | -162.2% | -138.8% | -131.4% |
| EPS Diluted | -1.13 | -1.59 | -1.95 | -1.69 |
| % Growth | 28.9% | 18.5% | -15.4% | – |
| Operating Cash Flow | -$5,667 | -$3,896 | -$3,479 | -$2,724 |
| Capital Expenditures | -$5 | -$7 | -$14 | -$0 |
| Free Cash Flow | -$5,672 | -$3,903 | -$2,487 | -$2,724 |